Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activin type II receptors (ActRIIA and ActRIIB) are transmembrane serine/threonine kinases belonging to the TGF-β receptor family. They play a crucial role in signal transduction for TGF-β ligands like activins, myostatin, and GDF11, influencing cell growth, differentiation, apoptosis, muscle mass regulation, and other processes. Upon ligand binding, they form heterotetrameric complexes with type I receptors, leading to Smad protein phosphorylation and gene expression modulation. Dysregulation is associated with diseases like myopathy and leukemia, making them therapeutic targets for muscle-wasting conditions and certain cancers.
Ligand binding induces heterotetramer formation with type I receptors, followed by phosphorylation of Smad proteins and subsequent gene expression changes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activin Type II Receptor (ActRII).